Table 1.
FDA-approved therapeutic mAbs and conjugates for cancer therapy
| Target | mAb | MOA | Indication | Reference |
|---|---|---|---|---|
| CCR4 | Mogamulizumab | ADCC | Mycosis fungoides, Sézary syndrome (approved in 2018) | 2 |
| CD19 | Tafasitamab | ADCC/ADCP | DLBCL (approved 2020) | 3 |
| CD20 | Rituximab | CDC/ADCC/PCD | B-NHL, DLBCL, CLL, FL (approved in 1997, 2006, 2010, 2011) | 4–7 |
| CD20 | Ofatumumab | CDC/ADCC/PCD | CLL (approved in 2009) | 8 |
| CD20 | Obinutuzumab | CDC/ADCC/PCD | CLL, FL (approved in 2013, 2016) | 9, 10 |
| CD38 | Daratumumab | ADCC / CDC / ADCP Blockade of CD38 |
MM (approved in 2016) | 11 |
| CD38 | Isatuximab | CDC/ADCP/ADCC | MM (approved in 2020) | 12 |
| CD52 | Alemtuzumab | ADCC/CDC/ADCP | B-CLL (approved in 2001) | 13, 14 |
| SLAMF7 | Elotuzumab | ADCC | MM (approved in 2015) | 15 |
| BCMA | Belantamab mafodotin-blmf | ADC | MM (approved in 2020) | 16 |
| CD20 | Ibritumomab tiuxetan | ADC | B-NHL, FL (approved in 2002) | 17 |
| CD22 | Inotuzumab ozogamicin | ADC | ALL (approved in 2017) | 18 |
| CD22 | Moxetumomab pasudotox | ADC | HCL (approved in 2018) | 19 |
| CD30 | Brentuximab vedotin | ADC | HL, ALCL (approved in 2011, 2018) | 20, 21 |
| CD33 | Gemtuzumab ozogamicin | ADC | AML (approved in 2017, 2020) | 22, 23 |
| CD79b | Polatuzumab vedotin | ADC | DLBCL (approved in 2019) | 24 |
ADC, antibody-drug-conjugate; ALCL, anaplastic large cell lymphoma; B-NHL, B-cell non-Hodgkin lymphoma; HCL, hairy cell leukemia; MOA, mode of action; PCD, programmed cell death.